ISP (N = 32) | CSP (N = 157) | p | |
---|---|---|---|
Age (y.o) | 40.9 ± 12.7 | 36.9 ± 12.9 | 0.08 |
Male gender (n [%]) | 15 (46.9) | 66 (42.0) | 0.61 |
BMI (kg/m2) | 22.3 ± 3.9 | 21.9 ± 3.6 | 0.46 |
HT (n [%]) | 18 (56.3) | 86 (54.8) | 0.88 |
DM (n [%]) | 1 (3.1) | 3 (1.9) | 0.53 |
SBP (mmHg) | 116.6 ± 14.8 | 116.6 ± 15.5 | 0.97 |
DBP (mmHg) | 71.5 ± 11.6 | 69.2 ± 10.6 | 0.27 |
RAS inhibitor use (n [%]) | 13 (40.6) | 79 (50.3) | 0.32 |
Proteinuria (g/gCr) | 0.93 (0.61–1.37) | 0.95 (0.36–1.52) | 0.77 |
Categories for proteinuria (g/gCr) | 0.16 | ||
≧1.0 (n [%]) | 14 (43.8) | 74 (47.1) | |
0.5–0.9 (n [%]) | 11 (34.4) | 31 (19.7) | |
< 0.5 (n [%]) | 7 (21.9) | 52 (33.1) | |
Hematuria (n [%]) | 29 (90.6) | 148 (94.3) | 0.54 |
eGFR (mL/min/1.73 m2) | 62.5 (33.9–80.7) | 70.7 (52.0–89.9) | 0.08 |
CKD stage | 0.39 | ||
1–2 (n [%]) | 18 (56.3) | 106 (67.5) | |
3 (n [%]) | 9 (28.1) | 40 (25.4) | |
4 (n [%]) | 5 (15.6) | 11 (7.0) | |
5 (n [%]) | 0 (0) | 0 (0) | |
IgA (mg/dL) | 346.6 ± 147.9 | 334.8 ± 122.3 | 0.92 |
C3 (mg/dL) | 97.4 ± 19.8 | 101.4 ± 20.1 | 0.38 |
IgA/C3 | 3.7 ± 1.9 | 3.4 ± 1.4 | 0.81 |
Tonsillectomy (n [%]) | 4 (12.5) | 68 (43.3) | < 0.05 |